Dupilumab leads to no or low disease activity in most moderate-to-severe atopic dermatitis patients: signs, symptoms and quality of life

被引：0

作者：

Blauvelt, A. ^{[1
]}

Chen, Z. ^{[2
]}

Hultsch, T. ^{[3
]}

Eckert, L. ^{[4
]}

Gadkari, A. ^{[2
]}

Shumel, B. ^{[2
]}

Ardeleanu, M. ^{[2
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR USA

[2] Regeneron Pharmaceut, Tarrytown, NY USA

[3] Sanofi Genzyme, Cambridge, MA USA

[4] Sanofi, Chilly Mazarin, France

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2018年 / 179卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P079

引用

页码：60 / 60

页数：1

共 50 条

[1] Dupilumab improves signs, symptoms, and quality of life in adolescents with moderate to severe atopic dermatitis
Eichenfield, Lawrence F.
Silverberg, Jonathan I.
Gadkari, Abhijit
Guillemin, Isabelle
Chen, Zhen
Bansal, Ashish
Eckert, Laurent
Rosner, Karli
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB26 - AB26
[2] DUPILUMAB IMPROVES SIGNS AND SYMPTOMS ASSESSED BY SCORAD IN ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Blume-Peytavi, Ulrike
Baselga, Eulalia
Gooderham, Melinda
Chen, Zhen
Abramova, Alvina
Worrell, Richard
Rossi, Ana
INTERNAL MEDICINE JOURNAL, 2021, 51 : 25 - 25
[3] Dupilumab in the treatment of moderate-to-severe atopic dermatitis
Kraft, Magdalena
Worm, Margitta
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (04) : 301 - 310
[4] Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis
James E. Frampton
Hannah A. Blair
American Journal of Clinical Dermatology, 2018, 19 : 617 - 624
[5] Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis
Frampton, James E.
Blair, Hannah A.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (04) : 617 - 624
[6] Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, Lisa A.
Thaci, Diamant
Hamilton, Jennifer D.
Graham, Neil M.
Bieber, Thomas
Rocklin, Ross
Ming, Jeffrey E.
Ren, Haobo
Kao, Richard
Simpson, Eric
Ardeleanu, Marius
Weinstein, Steven P.
Pirozzi, Gianluca
Guttman-Yassky, Emma
Suarez-Farinas, Mayte
Hager, Melissa D.
Stahl, Neil
Yancopoulos, George D.
Radin, Allen R.
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (02): : 130 - 139
[7] COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab
Ungar, Benjamin
Glickman, Jacob W.
Golant, Alexandra K.
Dubin, Celina
Marushchak, Olga
Gontzes, Alyssa
Mikhaylov, Daniela
Singer, Giselle K.
Baum, Danielle
Wei, Nancy
Sanin, Antonio
Gruenstein, Diana
Lebwohl, Mark G.
Pavel, Ana B.
Guttman-Yassky, Emma
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (01): : 134 - 142
[8] Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
Cork, M. J.
Eichenfield, L. F.
Blauvelt, A.
Rosmarin, D.
Hussain, I.
Davis, J. D.
Li, M.
Zhang, Q.
Gadkari, A.
Eckert, L.
Kamal, M. A.
Bansal, A.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S104 - S104
[9] Efficacy and tolerance of dupilumab in patients with moderate-to-severe atopic dermatitis and obesity
Dupuis, Josephine
Tauber, Marie
Mahe, Emmanuel
Jachiet, Marie
Soria, Angele
Tetart, Florence
Puzenat, Eve
Pasteur, Justine
Raison-Peyron, Nadia
Giordano-Labadie, Francoise
Droitcourt, Catherine
Leleu, Camille
Nosbaum, Audrey
Aubert, Helene
Moigne, Marie L. E.
Bernier, Claire
Barbarot, Sebastien
Ezzedine, Khaled
Diaz, Emmanuelle
Hubiche, Thomas
Faiz, Sarah
Azib, Selma
Dezoteux, Frederic
Chosidow, Olivier
Staumont-Salle, Delphine
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025, 39 (02) : e174 - e178
[10] Treatment satisfaction in patients receiving dupilumab for moderate-to-severe atopic dermatitis
Lans, A.
Van der Schaft, J.
Bakker, D.
Ariens, L.
Thijs, J. H.
De Bruin-Weller, M. S.
Balak, D. M. W.
ALLERGY, 2019, 74 : 82 - 82

← 1 2 3 4 5 →